All members of the Metabolomics Society are welcomed and encouraged to participate in the 2022 Board of Directors election. Voting is open now through August 29, 2022, at 11:59pm USA CST. Complete details on elections can be found here.
This webpage contains a list of nominees as well as biographies and statements of interest regarding serving on the Board. Please take a moment to review this information before placing your votes.
Biography: Dr. Giallourou has an international academic profile, with studies in the United Kingdom, the Netherlands and the U.S. and participation in research projects across the world. Dr Giallourou earned her PhD in Nutritional Metabolomics from the University of Reading in 2017 and subsequently joined the Department of Metabolism Digestion and Reproduction at Imperial College London. In 2020 she was awarded the prestigious Marie Sklodowska-Curie Individual Fellowship to work on the integration of metabolomic and genomic data in population-based studies for the identification of composite genotype-phenotype determinants of complex diseases and improved patient stratification. She is currently a Postdoctoral Fellow at the Centre of Excellence in Biobanking and Biomedical Research of the University of Cyprus where in parallel to her research interests, she facilitates the implementation of metabolomics in the Centre’s biobanking activities.
Dr Giallourou is an active member of the Metabolomics Society since 2018. She sits on the Board of Directors since 2020 and served as Chair (2019-2020) of the Early-career Members Network (EMN) committee to which she is now an Advisor. She is a member of the Metabolomics Society’s Education and Training committee and Conference committee. She participates on the Society Strategy Task Group as working on the development of initiatives for the support scientists in metabolomics. She is also a member of the Diversity, Equity and Dr Giallourou co-chaired the 18th Conference of the Metabolomics Society held in Valencia in June 2022.
Statement of Purpose: My participation in the Metabolomics Society to date has been very rewarding and I am eager to extend my contributions to the metabolomics community. If re-elected as director I intend on working on the following goals:
1) To work towards a more inclusive and diverse Society: I am keen to participate in the Society’s efforts aimed at promoting diversity among its members and help foster an inclusive environment of scientific collaborations in metabolomics welcoming and encouraging participation from everyone, in all levels and areas of societal activity.
2) To continue supporting the EMN: I will work with the EMN to help effectively maintain continuity in ongoing projects and initiatives and assist them in aligning their future programs with the Society’s strategy and community needs. In particular, I am interested in contributing to areas pertaining to the critically important training needs of early-career scientists and work on the networking opportunities offered by the Society.
3) To lead and co-ordinate the Society’s Conference Committee activities. Chairing and organising the meeting in Valencia has equipped me with the skills and knowledge to fulfil this role. I will work towards the identification of opportunities to amplify the conference’s quality and impact.
My enthusiasm, scientific expertise, EMN and Board experience will enable me to advance my goals for the benefit of our community.
Biography: Roy Goodacre is Professor of Biological Chemistry at the University of Liverpool and a co-director of the Centre for Metabolomics Research. He helped to develop and establish long-term metabolomics which allows fusion of GC-MS and LC-MS data. These approaches have been used by his team and collaborators to profile health populations and investigate the frailty phenotype during the ageing process. In parallel, in order to understand metabolic flux on a single cell level for bacterial community analysis, his group are currently developing high spatial resolution photothermal infrared and Raman-based imaging methods. Roy has published a substantial number of primary papers and reviews in metabolomics and data processing as well as Raman spectroscopy (https://goo.gl/B3yWRC), and if you like such metrics he has a H-index of over 100.
Statement of Purpose: Roy helped establish the Metabolomics Society in 2005, chaired the Society’s conference in Manchester in 2007, was involved in the Society’s Metabolomics Standards Initiative (MSI) and acted as the chair for the MSI data analysis work group, a role he is currently revisiting. He has been a member of the Board of Directors of the Metabolomics Society for the last two years and would like to serve for a second term. With a track record in conference, committee organisation and delivering projects on time, he would be immensely honoured to serve the society. Roy believes that diversity and inclusivity are paramount in all organisations and would further embed this within the Metabolomics Society. He would support the further development of ECR training and activities, endeavour to promote metabolomics globally, as well as to encourage regional developments in this exciting field.
Biography: Fabien Jourdan is a senior research scientist at INRAE (the French National Research Institute for Agricultural and Environmental Research) Toulouse, France. He graduated with a PhD in computer science at the University of Montpellier (France) in 2004, working on the premises of social networks, in particular studying their topology. He then shared his time between a software startup company and a research assistant position. In 2005 he was hired by INRAE (Toulouse, France) to develop computational solutions for metabolomics studies (mainly NMR). In 2006 he spent a year as a visiting researcher at the University of Glasgow working with Pr. Barrett on metabolic profiling (HRMS) of Trypanosoma brucei, a parasite and causative agent of sleeping sickness.
Fabien Jourdan has pioneered bioinformatics methods to study Genome-Scale Metabolic Networks using metabolomics (and other omics data) to predict metabolic impacts associated with genetic or environmental perturbations. His research team is currently applying these approaches to food toxicology and more broadly in studying the link between metabolism and human health (e.g. cancer). Since 2009, Fabien Jourdan has led the development of MetExplore open access web server which is used by more than 800 users worldwide and maintained and developed by a group of 10 computational biologists. Since 2021, Fabien Jourdan is director of the French National infrastructure for metabolomics and fluxomics, MetaboHub. He was president of the French-speaking Metabolomics and Fluxomics Network (RFMF) from 2015 to 2019. He was elected on the board of the metabolomics society in 2019 and is secretary since 2020.
Statement of Purpose: Serving as a board member and secretary since 2019 has been an honor. In addition to board activities, I worked on improving the award process. I would like to pursue that by increasing the visibility of the awardees (invited talks during the conference). I was involved in the communication activities like revamping the website. I reactivated the tweeter account of the society (from 500 new followers per year to 900). With the president, we worked on the affiliations of regional networks (Latin America, Poland). Promoting them is essential since they are key in disseminating metabolomics and supporting young scientists worldwide.
Beyond going further in my initiatives, if elected, I would like to be part of the effort to increase diversity in our community through support of regional societies and increase open online resources. I would also like to stay active in the digital transition which allows reducing financial barriers to access cutting edge science. I would like to pursue supporting EMN by providing more visibility through communication to facilitate kicking off young scientist careers. On a scientific point of view, one of the challenges I foresee is the interpretations of metabolomics data. We need to foster connections with data mining, visualization and network science. We managed to stay united during the pandemic and we all felt the genuine joy of meeting again in person during MetSoc2022, showing that science is above all a human adventure and the Society is there to accompany us in shaping the future of metabolomics community.
Biography: Matej Orešič holds a PhD in biophysics from Cornell University (1999; Ithaca, NY, USA). He is professor of medicine, with specialization in systems medicine at Örebro University (Sweden) and a group leader in systems medicine at the University of Turku (Finland). As of 2016, he became a Lifetime Honorary Fellow of the Metabolomics Society. He is current member of the Board of Directors of the Metabolomics Society. He also previously served the Society in this role for two, consecutive terms (2008-2012). Prof. Orešič is one of the founders of the Nordic Metabolomics Society and its previous chair of the board. In 2019, he co-chaired the 1st Gordon Research Conference on ‘Metabolomics and Human Health’ (Ventura, CA). Previously, he also chaired the Keystone Symposium on Systems Biology of Lipid Metabolism (2015; Breckenridge, CO). Main research areas of Prof. Orešič include metabolomics applications in biomedical research and systems medicine. He is particularly interested in the identification of environmental exposures (exposome) and disease processes associated with different metabolic phenotypes and the underlying mechanisms linking these processes with the development of specific disorders or their co-morbidities. Prof. Orešič also initiated the popular MZmine open source project, leading to popular software for metabolomics data processing.
Statement of Purpose: With its rapid growth over the past decade, metabolomics, along with its various subfields such as lipidomics, fluxomics, and metabolic modeling, has become an essential tool in the life science and biomedical research, also playing a central role in shaping the emerging fields such as exposome, gut microbiome and systems biology research. At the community level, this growth can be observed as increasing participation in various metabolomics meetings, many new training opportunities for young scientists, the formation of many regional initiatives (some of which are already affiliated with the Metabolomics Society), as well as by increased efforts in data reproducibility and harmonized reporting. With such a rapid growth, there is risk of fragmentation of these important, nascent efforts of the community. In my role as member of the board, I will continue strengthening the efforts to realize the core mission of the Metabolomics Society, as being a global hub that supports these various initiatives and facilitates coordination between them when relevant or necessary. Specifically, this will include:
1) Stronger participation of regional metabolomics initiatives in annual meetings of the Metabolomics Society (e.g., workshops, receptions).
2) Strengthening ties with other scientific communities in subfields or related fields of metabolomics (e.g., exposome research, gut microbiome, lipidomics), including in efforts to develop good practices in the field and related dissemination.
3) Support for establishing metabolomics in high-profile scientific meetings such as at Gordon Research Conferences and Keystone Symposia.
Biography: Stacey Reinke is a Senior Lecturer in Applied Statistics and Computational Biology at Edith Cowan University (Perth, Australia). She completed her PhD in Biochemistry at the University of Alberta (Canada) in 2011. Her early research investigated mitochondrial dysfunction in model systems, which later expanded to investigating energy metabolism dysregulation in inflammatory diseases. During her first postdoctoral position, Stacey worked closely with David Broadhurst which fostered her interest in design of experiments and data science. Upon receiving a Canadian Institutes of Health Research Fellowship in 2014, Stacey relocated to the Karolinska Institute (Sweden) where she worked under the mentorship of Craig Wheelock. During this time, she played a key role in developing large-scale clinical metabolomics workflows for as part of the EU-wide UBIOPRED asthma project. In 2016, Stacey was recruited to Perth (Australia) as part of a state-led initiative to enhance clinical metabolomics capacity in Western Australia. Stacey’s primary research focus is on respiratory diseases. As a teaching-research scholar, she is also passionate about teaching and recently completed a Graduate Diploma in Tertiary and Workplace Education.
Statement of Purpose: At the beginning of my first term on the Board of Directors, I was appointed Chair of the Training Committee. The committee consists of both Board of Directors and general members of the Metabolomics Society. My first action as chair was to lead the restructure of the committee to reflect a more diverse portfolio and the growing needs of the metabolomics community. This involved renaming the committee to the Education & Training Committee and establishing a clear and focussed mission statement outlining our strategic commitment to support these two different but complementary learning processes. In May 2022 we launched a Podcast-style webinar series to support our new mission. By nature, metabolomics is both an inter-disciplinary and non-standardised field of science. Accordingly, metabolomics research requires cross-disciplinary content knowledge, subjective experience-based judgement, and application of a diverse technical skill set. This educational series aims to support novice metabolomics researchers in developing their critical thinking and decision-making skills so that they feel more confident in their research practice. We aim to host these series quarterly, with the intent of building a repository of resources over time for the community. Finally, to facilitate the development and delivery of high-quality training and education initiatives in the broader metabolomics community, we prepared a pedagogical guidance manuscript. This manuscript is currently under review, and we hope to have it published in the coming months. If re-elected for a second term on the Board of Directors, I will continue to Chair the Education & Training Committee, building on the momentum that we have established over the last term, and continue to drive new initiatives to support the needs of the metabolomics community.
Biography: Originally from Rwanda (and currently living in South Africa, SA), Dr. Tugizimana holds a Ph.D. in Biochemistry (UJ). He has received different non-degree purpose training in Advanced Mathematics (UNISA) and in Metabolic modelling, Pathway and Flux analyses (Wageningen University, Netherlands). I am currently a specialist scientist in the International R&D management of the Omnia Group Ltd. SA, a Lecturer and research scientist in the Department of Biochemistry at UJ, a scientific consultant in the L.E.A.F. Pharmaceuticals LLC (USA & Rwanda).
I apply metabolomics approaches in interrogating cellular biochemistry at global level, specifically in plant-environment interactions, plant biostimulants, natural products research and infectious diseases. Furthermore, I am involved in driving the implementation of tools and workflows developed and used in extracting information from metabolomics data. Currently I’m interested in exploring 4IR technologies in metabolomics, the use of machine learning and integrated novel computational frameworks in mining and interpreting metabolomics spectral data. I collaborate with different international scientists in the field.
I’m an active member of SA scientific societies, the Metabolomics Society (as a member of different committees and task groups). I am involved in metabolomics training in SA, and have been involved in the establishment of the Metabolomics South Africa (MSA), an affiliate to the Metabolomics Society since June 2018. Dr. Tugizimana is an author/co-author of several metabolomics papers in leading peer-reviewed international scientific journals; and he serves as a guest editor and a reviewer for scientific journals such as Metabolomics, Frontiers in Plant Science, Metabolites, Nature Communications and Scientific Reports.
Statement of Purpose: If trusted and elected the 2nd term for a director position on the BoD of the Metabolomics Society, I would like to continue serving the Society (and the metabolomics community in general) in ways that promote the growth, use and understanding of metabolomics in the life sciences across the globe, and particularly in South Africa and in Africa in general. Being active member (President) of the Metabolomics South Africa (MSA) (with about 250 members from across Africa), increasing (Society) membership in Africa is one of the focus areas of MSA; and this is done through developing initiatives and framework to increase interactions between the Society and MSA (which expands to other parts of Africa) via networking, training, and collaborations. The metabolomics training workshops we (MSA) have started in South Africa are always highly attended in numbers (from SA and across Africa), showing the great need for understanding and use of metabolomics in life sciences in SA and Africa in general. And this, visibly, predicts a significant growth of metabolomics in Africa. Furthermore, I look forward to contribute in the aspects of data quality, data standards initiatives and computational tools for data mining and interpretation. Thus, when elected (for the 2nd term) as a director, and as part of the team, promotion of metabolomics in South Africa and Africa, training, data quality and standardization initiatives, DEI promotion and networking will be my areas of contribution and focus.
Biography: Dr. Michael Witting studied Applied Chemistry with a functional direction into Biochemistry at the Georg-Simon-Ohm University of Applied Sciences Nuremberg and obtained his PhD in 2013 from the Technical University of Munich. Since 2021 he is heading the metabolomics part of the Metabolomics and Proteomics Core of Helmholtz Munich. In 2018 he was named on the Top 40 under 40 Power List of The Anaytical Scientist. He is an active member of the Metabolomics Quality Assurance and Quality Control Consortium (mQACC), the International Lipidomics Society and the Metabolomics Society, where he served as member on the Board of Directors from 2020 to 2022.
Statement of Purpose: I have been previously involved as director from 2020 to 2022 and been actively involved in the 2022 meeting as well as being active for example in the Education and Training Committee. As director in the next term, I would like to foster the collaboration between different societies that are related to metabolomics for example the International Lipidomics Society, but also others like “The Association for Mass Spectrometry & Advances in the Clinical Lab” or “International Federation of Clinical Chemistry and Laboratory Medicine”. These societies have metabolomics sections or are related to potential applications of metabolomics as well as offering training and education, e.g. in mass-spectrometry. A goal in order to promote metabolomics together as whole is to implement common understanding of each other, support for training and education and joint events. As director I would like to start a dialogue with different societies about common topics and goals.
Biography: Will has researched in the field of metabolomics (inclusive of lipidomics and volatilomics) for over 18 years. Will first gained a passion for mass spectrometry whilst applying MALDI-MS to bacterial identification and during his PhD applying metabolomics to study plant pathogen interactions, gaining recognition as one the first teams applying metabolomics in the field. Will went on to provide metabolomics services and project management within the Universities of Manchester and Birmingham across plant, microbiological and clinical, areas. In 2015 Will moved to Scotland where he took responsibility for the LC- and GC-MS metabolomics services at James Hutton Institute, where he serves as a senior research scientist and deputy leader of the Plant Biochemistry and Food Quality programme. Will also currently serves as the chair of the Scottish Metabolomics Network.
Will’s research passion is focused on the development of chromatography – linked – MS (primarily LC, but also GC) for a range of applications in plant-physiology, pathology and insect interactions, natural products and food quality. Will is particularly skilled in the development of high-resolution liquid chromatographic separations, both reverse phase and normal phase/HILIC, with single and two-dimensional separations. Will is also interested in the application of accurate mass MSn approaches that are essential for the identification of complex plant secondary metabolites. Will collaborates with a number of labs who are specialised in two-dimensional NMR analyses, combining information from both NMR and MSn to characterise compounds at the three-dimensional level of structure.
Statement of Purpose: As a committed plant researcher, Will would be passionate first and foremost to promote plant biochemistry and metabolomics research within the Metabolomics Society, maintaining that the society retains an equal focus between plant/food/environmental, technological and clinical areas of application, as well as maintaining that the board consists of members representing plant metabolomics, as well as clinical and technological areas. When Will commenced working in the field, plant research was at the forefront of metabolomics, he is therefore committed to re-establishing that the plant sciences are supported and recognised as strongly as the clinical, technological and computational sciences within the society. Will would be keen to contribute workshops in the areas of chromatographic separations and MS based metabolite identification on behalf of the metabolomics society. Will would also be keen to contribute to the already established task groups in Metabolite Identification, Data Quality and Data Standards, where he is experienced and able to make strong contributions. As current chair of the Scottish Metabolomics Network, Will would also be keen to contribute and advance relations between the international affiliates’ group, pushing forward programmes for student exchanges with respect to laboratory and technology exchange visits, as well as training network workshops, and travel bursaries for early career researchers to attend annual meetings hosted by the respective affiliates.
Biography: Philip Britz-McKibbin is a Professor at the Department of Chemistry and Chemical Biology and Cystic Fibrosis Canada Researcher at McMaster University in Hamilton, Canada. Philip obtained his BSc in Chemistry (U. Toronto, 1994), and PhD in Analytical Chemistry (UBC, 2000) and a Japan Society for Promotion of Science PDF position in Japan (Hyogo University, 2001-2003) prior to starting his academic position at McMaster. His research group is also an affiliate member of The Metabolomics Innovation Centre (TMIC) – Canada’s national metabolomics laboratory. His research interests in bio-analytical chemistry, separation science, mass spectrometry and metabolomics include the design of novel analytical strategies to quantify and identify metabolites of clinical significance in biological samples. Philip’s laboratory aims to discover new biomarkers that support early detection of inherited diseases and chronic disorders which can be applied to understand the developmental origins of disease. His research interests include the development of high throughput screening methods for large-scale epidemiological studies in metabolomics in order to improve the measurement of smoke exposure and habitual diet as compared to self-reports from questionnaires.
Statement of Purpose: If elected as a member of the board of directors at the Metabolomics Society, I would contribute to several committees and scientific task groups that reflect my passion and experience in translational metabolomics research and scientific transparency. Given an ongoing reproducibility crisis in science, I would be pleased to lead new initiatives in the data analysis task group that harmonize both metabolomic and lipidomic reporting standards for both research communities. I can contribute to the epidemiology task group due to the major technical barriers in conducting large-scale yet cost-effective metabolomic analyses that are also practical for developing countries. Also, I would be interested in leading a new task group that can focus on expanding exposomic initiatives as a way to evaluate the environmental determinants of health and disease. Lastly, I would be pleased to lend my support to the Training and Conference Committees as key outreach activities to better promote metabolomics research to a new generation of young investigators.
Biography: Karl Burgess is Senior Lecturer in Biological Mass Spectrometry at the University of Edinburgh, Research Impact Director for the School of Biological Sciences and Scientific Director of the EdinOmics mass spectrometry core facility. Karl spent ten years as Head of Metabolomics at Glasgow University’s Polyomics Facility before making the transition to academia in Edinburgh. Throughout his career, Karl has focused on new workflows and technologies supporting diverse applications, most notably in stem cell differentiation, parasitology and clinical research, with more than 70 papers in the field. His current research focuses on enhancing biotechnology via high throughput cell line metabolomics and high-resolution on-line fermentation analysis. Karl has a strong track record of working with industry, from instrumentation vendors to small/medium biotech companies, and likes solving practical problems using metabolomics. Over the last couple of years he has particularly missed the opportunity to meet friends (both old and new) in person at the Metabolomics Society conference and was excited to recently participate in the Valencia meeting. He hopes that the next few years are an opportunity to strengthen our international networks and bring more people into this exciting and supportive field.
Statement of Purpose: Karl founded the Scottish Metabolomics Network in 2014 (now a member of the international affiliates programme) and was chair of the network from 2014-2019. He is a member of the Best Practices Group for the Metabolomics Quality Assurance and Quality Control Consortium (MQACC), Member of the Board of Directors of the Metabolite Profiling Forum, and a co-organiser of the 2013 Metabolomics Society conference and the 2019 Scottish Metabolomics Symposium in Glasgow. Karl enjoys training and teaching, notably on the Polyomics and University of Pretoria short courses on metabolomics. As a member of the Metabolomics Society Board, he would focus on ensuring our understanding of best practice, experimental design and responsible reporting standards is disseminated as widely as possible, particularly to industry, early career researchers and emerging metabolomics laboratories worldwide.
Biography: Dr. Leo Cheng is an Associate Professor of Radiology at Harvard Medical School (HMS) and Massachusetts General Hospital (MGH). He was born in China, and came to the US to study as a Biophysicist specialized in NMR. Following his doctoral training with Profs. Judith Herzfeld at Brandeis University and Robert G. Griffin at MIT in solid-state NMR in 1993, and during his post-doctoral study at MGH/HMS, he pioneered high-resolution-magic-angle-spinning (HRMAS) NMR for biological specimen analyses. This methodology presented NMR with capabilities that were, and still are, not achievable with any other method, including acquiring high-resolution spectra without tissue pathological destruction and measuring sensitive NMR spectra from less than 10ul biological fluids. In the past 25+ years, using this technology, his laboratory has concentrated on biomarker research and later developed NMR-based intact tissue metabolomics for human health. Through these studies, he investigated a cascade of diseases, including human prostate cancer aggressiveness, human lung cancer serum screening, and pioneered NMR metabolomics imaging. In that capacity and as an expert of NMR associated medical imaging, he has advised multiple funding agencies nationally and internationally since 2003, including more than 70, as well as two four-year terms as a charter member in NIH study sections. he has been on the editorial board of NMR in Biomedicine since 2005, and currently he is a member of mQACC, and serves as its co-Secretary. He joined the Metabolomics Society during the COVID, and with colleague supports, successfully organized a “Frontiers in NMR Metabolomics” Workshop during Metabolomics 2022.
Statement of Purpose: My work with NMR-based metabolomics for medical applications has equipped me with the first-hand knowledge on the importance of metabolomics in human health. More critical than scientific knowledge, my work with my trainees and fellows have taught me the importance of training the next generation scientists in diverse and inclusive environments.
If being elected to the BoD, I will use this effective platform to achieve the following objectives:
1) Training Next Generations. Using my experiences acquired from diversity, equity, and inclusion (DEI) committees both locally at Harvard Medical School and internationally with World Molecular Imaging Society, I will work with our Early Career Member’s Network (EMN) to emphasize on training both of DEI and with less-represented early career metabolomics scientists, though organizing trainee symposiums and enticing sponsorships.
2) Promoting Multi-platform Metabolomics. Utilizing my expertise in NMR metabolomics, I will work across disciplines to promote incorporations of metabolomics data obtained from different technologies, with the ultimate goal of their applications in medicine and human health through both biofluid examinations and in vivo multi-platform guided metabolomics imaging.
3) Outreaching Collaborations. Metabolomics utilizations in medicine will need a broad community effort. Our society will need to reach out to other medical societies and associations, such as ISMRM, WMIS, AACR, etc. to introduce them with our unique capabilities and insights for assessing human disease and supporting human health. Such outreaches will also be critical for the further development and nourishment of our society. I will work to establish and strengthen these inter-society collaborations.
Professor in Analytical and Clinical Metabolomics
School of Biosciences
University of Birmingham
Birmingham, B15 2TT, U.K.
Prof. Warwick (Rick) Dunn obtained a BSc (Hons) degree in Chemistry with Analytical Chemistry and Toxicology at The University of Hull followed by a PhD at BP Chemicals and The University of Hull focused on the placement of mass spectrometers on industrial chemical process plants. He has developed a passion for academic life and from 2003-2012 he worked at The University of Manchester, first as a post-doctoral researcher with Professor Douglas Kell and then as a Lecturer in Metabolomics. He moved to the University of Birmingham in early 2013 and is currently a Professor in Metabolomics, Director of Mass Spectrometry in Phenome Centre Birmingham and Director of the Birmingham Metabolomics Training Centre. Warwick has performed metabolomics research for 19 years and has concentrated his research on analytical and software tool development and their application in untargeted and targeted assays. He has a passion for maximising metabolite annotation in untargeted studies and has developed tools for conversion of m/z to putative metabolite annotations (PUTMEDID_LCMS) and in optimal acquisition of MS/MS data. Away from development work he focuses on the study of metabolism during human ageing and in human diseases to understand pathophysiological mechanisms and identify prognostic or diagnostic biomarkers for stratified medicine. Warwick is currently Associate Editor (Reviews) for the journal Metabolomics and is a past-director of the Metabolomics Society (2010-2015). Warwick has published greater than 120 peer-reviewed papers (>12,500 citations) and 6 book chapters.
Statement of Purpose: Driving metabolomics forward has been a passion of mine for 20 years, both from a scientific aspect but also in supporting the metabolomics community through conferences and workshops (e.g. Metabolomics Society, MetaboMeeting), societies (Metabolomics Society), consortia (mQACC) and training (through training centres and Society-led training opportunities). The metabolomics society had driven itself forward significantly and I want to lead on driving it further forward as a community both as developers and users of metabolomics but also as promoting metabolomics to other research fields. My goals as a Director will be (1) to ensure the Society works for every researcher across the world and every researcher can contribute to the society through membership and events; (2) to ensure early career researchers or researchers new to the research area have availability of varied and appropriate training, educational and networking resources; (3) to ensure metabolomics is considered as a tool in all life sciences research through engagement with other societies and organisations including industry and academia and (4) to promote open science for data sharing and to ensure use of quality and reporting standards. I am already a member of the training committee and am co-chair of the metabolite identification task group which has shown my commitment to the society when I was not a Director. If elected I would like to chair one of the committees (conference, training or membership) and become significantly involved in the industry engagement and society strategy task groups.
Biography: Dr. Evans has led the Research and Development group for the discovery metabolomic and lipidomic profiling technologies at Metabolon for the past 18 years, and instrumental in the evolution of the metabolomic and lipidomic platforms to their current status of operations in the company. These developments have been foundational in providing high quality metabolomics outputs supporting thousands of commercial and academic studies from over 800 institutions worldwide since 2004. She has over 30 publications covering analytical methodology as well as informatics, data processing, quality management, and approaches for global profiling metabolomic and lipidomic workflows directed toward precision medicine applications. Her work has been cumulatively cited over 2000 times. These publications have spanned various technology journals such of the Analytical Chemistry, biological journals such as Blood and PNAS as well as high impact journals such as Nature Genetics. Dr. Evans currently holds an h-index of 35, with a JCR of 13. Dr. Evans received her Ph.D. in chemistry from the University of Virginia where her research was focused on MS based proteomics with Dr. Donald Hunt. Currently, her research is focused on further developing next generation of Metabolon’s metabolomic and lipidomic platforms as well as actively investigating technologies to be able to support future focused initiatives. She is currently engaged in leveraging the most advanced version of the developed platform supporting establishment of metabolomic benchmarks in population health studies and beyond. Dr. Evans is an active member of the Metabolomics Quality Assurance and Quality Control Consortium (mQACC), works closely with several large population health programs including TOPMed and COMETS and has been actively involved with harmonization efforts across metabolomics methodologies.
Statement of Purpose: I have dedicated my professional career to advancing the field of metabolomics and lipidomics to maximize its potential applications across multiple industries. It has been a privilege to be part of and participate in the growth of metabolomics and lipidomics application across many areas of sciences including life sciences for precision medicine, health and wellness. Being part of the Metabolomics Society Board, I will continue to actively drive the story of “why metabolomics?” to a wider scientific community. Specifically, focusing on education and demonstration of the unique insights that can be derived from metabolomics data while simultaneously understanding the challenges the scientific community encounters when interpreting metabolomics data. It is my belief that metabolomics data will continue to be used to better treat and diagnose individuals. I will be focused on working to spread adoption of metabolomics into mainstream “omics”, enable programs demystifying interpretation of metabolomics data, a perceived challenge within the larger scientific community and look for opportunities to address the future of metabolomics. I bring unique insights to the society through a lens having served a diverse base of investigators including leaders within metabolomics research like COMETs, TOPMed and pharmaceutical and corporate entities; lending to a deeper understanding of their respective needs of metabolomics. Given the opportunity, I am confident of bringing a unique perspective to the Metabolomics Society Board as the entirety of my career has been focused on providing metabolomics as a service to the various stakeholders interested in its potential applications.
Biography: I’m a Professor and Associate Chair for Research at the School of Chemistry and Biochemistry at Georgia Tech, in Atlanta, Georgia, USA. I am trained as a mass spectrometrist and have been working in metabolomics since 2005, where we started our first project on ovarian cancer. I did my PhD in Buenos Aires, Argentina, followed by a postdoc at Stanford University and a second one at the University of Arizona. I love research, teaching and mentoring, and I am constantly trying to balance the demands of work with my personal life. I am the proud father of two lovely kids. We like to travel, go camping in remote areas and enjoy the neighborhood pool in the hot Georgia summers.
Statement of Purpose: Growth in our society has followed the exciting growth in our field and will hopefully continue as we move forward. The success of the Valencia meeting highlights our resilience as a group. We now face the challenge of further increasing the visibility and significance of our Society so it continues to grow as the leading international forum for showcasing critical developments in metabolomic science, supporting and mentoring the next generation of scientists and disseminating knowledge . I’d like to contribute to playing a role in that path. I have a long standing interest in metabolomics, particularly from the analytical chemistry side of things. One of the areas I’d like to work on is regarding the society Journal, and finding the best possible forum for showcasing our members’ work.
Biography: Daniel Globisch is an Associate Professor of Analytical Chemistry at the Department of Chemistry at the Biomedical Center at Uppsala University in Sweden. Daniel also holds a guest affiliation at the Center for Microbiome Research (CTMR) at Karolinska Institute and is currently serving on the board of the Nordic Metabolomics Society. He received his PhD degree from the Ludwig-Maximilians-University Munich (Germany) in 2011, where he quantified natural RNA/DNA modifications using mass spectrometric techniques. For his postdoctoral studies, he joined The Scripps Research Institute (TSRI), La Jolla, CA (USA) to work on bacterial quorum sensing and metabolomics. During his 4,5-year postdoctoral research, Daniel Globisch discovered the biomarker N-acetyltyramine-O-glucuronide (NATOG) using a metabolomics mining approach for the neglected tropical disease onchocerciasis within the Worm Institute for Research & Medicine (WIRM), where was working as Assistant Director for Biomarker Discovery and Metabolomics Research for 2 years. He developed an antibody-based urine dipstick test for non-invasive diagnosis of NATOG. At Uppsala University, where he was recruited as a SciLifeLab Fellow, Dr. Globisch’s research focus lies on the development of unique Chemical Biology tools to enhance the scope of metabolomics research. His interdisciplinary projects integrate global metabolomics, (bio)organic chemistry, mass spectrometry as well as Chemical Biology approaches and are focused on elucidating the metabolic interaction between microbiota and their human host. He explores the potential of microbiome metabolism as a new strategy for the discovery of biomarkers for pancreatic, colorectal cancer and neurological diseases as well as unknown bioactive metabolites produced by the gut microbes.
Statement of Purpose: The multidisciplinary metabolomics community is rapidly expanding with new fields and subdisciplines emerging. This has already led to the development and invention of a series of powerful bioinformatic and chemical methods. However, one of the major limitations still remains the elucidation of the correct metabolite structures. This is crucial for the discovery of unknown metabolites produced by the microbiome, drug metabolites that are part of the dark matter of the metabolome to gain access to a wider metabolome and biochemical processes than today possible.
If I receive the honor to be elected as a member of the board of directors, I would support ongoing task groups within the Metabolomics Society and take the lead for new task groups within my areas of expertise and passion. With a new perspective from my Chemical Biology and microbiome background, these tasks forces would include i) streamlining metabolite ID, ii) the implementation of new technologies and tools for metabolomics, iii) integration of the microbiome metabolism with the host metabolism, and iv) strategies to uncover the unknown metabolome. I am also passionate about the support of Early Career Researchers to further extend the ongoing interactions with the EMN. Based on my experience within the Board of the Nordic Metabolomics Society, I would also take key roles to organize future society meetings and workshops.
Biography: I am Dr. Bryan Gonzales, an Asst Prof at Wageningen University, Netherlands since 2020. I am a Filipino scientist with a BSc in Food Technology (University of the Philippines Mindanao), and an Erasmus Mundus MSc in Food Science (University of Copenhagen, Denmark and Universitat Autonoma de Barcelona, Spain). I did my PhD at Ghent University (2012 – 2016, Belgium) where I published papers on the structure and metabolism of polyphenols using LCMS, ion mobility and QSAR. My career took a turn when I went to Turkmenistan and Uzbekistan to give capacity building trainings in lab analysis as a consultant for the World Health Organization Europe. There, I realised that I can use my analytical chemistry skills to improve public health; valuing real impact over papers. So, I took a giant leap of faith, jumped ship from doing LCMS analysis to focus my research on malnutrition in children. I was a fish out of water at first, but it trained me in epidemiology and biostatistics. I was an FWO postdoc fellow at Ghent University, and visiting scientist at the Hospital for Sick Children (Canada), Kenya Medical Research Institute – Wellcome Trust (Kenya), and University of Cambridge (UK). Now, I combine all my previous experience in nutrition, epidemiology and metabolomics to understand the pathophysiology of (severe) malnutrition in children. I am also a returning scientist in the Philippines, where I am pioneering the nutri-metabolomics research in the country. My team is composed of PhD students from Kenya, Philippines, Ethiopia, China and Netherlands.
Statement of Purpose: The tenure of a BoD is only 2 years (renewable once). Hence, I will not attempt to promise big changes and improvements to this already successful and respectable organization. Instead, my principle is to “Under-promise and over-deliver”. As a BoD, I will contribute my enthusiasm and energy to steer the organization further to accomplishing its mission and vision. I will use this platform to advocate for my passions, as follows:
1) Inclusion and Capacity Building. I will advocate for activities that build bridges between established labs and lower-resource labs or countries who are still starting in metabolomics. We often underestimate the capacity in the “Global South”, but there are scientists who are waiting to be involved in metabolomics. All they need is a chance and a platform. I am currently supporting the establishment of a metabolomics platform in the Philippines, the first, with the support of the Philippine Government. I aim to expand this, and also reach out to other countries in the Global South.
2) Statistical Metabolomics. Whilst many great advancements have been showcased in the past Metabolomics Conferences, positive reactions from my talks tell me that there remains a hunger from members to learn and apply better statistical approaches to their metabolomics data. Hence, I will advocate for activities to improve the application of proper statistical analysis to make metabolomics data more insightful in a clinical and epidemiological context. I am a student of causal inference; I firmly believe that the metabolomics field will benefit from causal thinking.
Biography: Dr Dong-Hyun Kim is Associate Professor in Analytical Bioscience in the School of Pharmacy at the University of Nottingham, which is ranked 5th in the world for Pharmacy and Pharmacology (QS World Rankings, 2022 and world-leading for research quality and impact for Pharmacy in the UK (REF2021)). He is Director of the Centre for Analytical Bioscience which is a successful mass spectrometry (MS) facility that now houses extensive specialist mass spectrometry instrumentation including high resolution MS (Thermo Exactive and QExactive), ion trap MS (Thermo LTQ Velos) and quadruple linear ion trap MS (QTRAP 4000 and 6500). This facility provides the high-quality research environment for metabolomics, lipidomics, fluxomics, metabolic pathway profiling, and biomarker identification analysis. His role includes coordination of internal and external project work as well as fostering interdisciplinary applications of MS-based analytical techniques. He is also Director of Metabolic Profiling Forum and has organised MetaboMeeting conferences since 2015. His research career has focused on the advancement and application of MS-based methods in order to solve scientific problems across the engineering/physical/life sciences disciplines attracting recent funding (>£4.5m) from various funding sources including BBSRC, ESPRC, MRC, NIHR, Brain Tumour Charity and RSC. He has a strong track record in fostering collaborative science where novel analytical approaches can make significant impacts on new areas of investigation. He has published over 60 peer-reviewed journal articles in top analytical and multidisciplinary journals on analytical science/biochemical methods and is supervising and line managing >20 PhD students, postdoctoral researchers and research officers in his research group.
Statement of Purpose: I think this is a great opportunity to work with the Metabolomics Society to contribute to growing the exciting metabolomics fields more rapidly. Through serving as a Director of the Board, I would like to make a substantial contribution to widen surface mass spectrometry (MS)-based metabolomics methods (e.g. liquid extraction surface analysis-MS (LESA-MS) and Orbitrap secondary ion MS (3D OrbiSIMS). 3D OrbiSIMS is a label-free analytical instrument which combines the high spatial resolution of SIMS (< 2 µm, subcellular level) with high mass accuracy and resolving power of an Orbitrap (>240,000 at m/z 200); University of Nottingham co-developed the technique and has only one in an academic setting in the UK at the moment. Introducing this new capability to the metabolomics communities will open the new level of understanding of human health, disease and wellbeing for life. I really want to integrate surface MS to the conventional metabolomics world! I would also like to contribute to making substantial progress on bridging metabolomics and wider scientific and research communities to solve biological/clinical problems more efficiently that researchers and scientists in a wide range of research areas may have. Lastly, I wish to promote education for junior members of the metabolomics community regarding experimental designs, rigorous normalisation of metabolomics data and clinical applications.
Biography: Dr. Biswapriya B. Misra, is currently a Director of Platform Metabolomics Innovation, at the Enveda Biosciences, where he is driving drug discovery using mass-spectrometry-based multiomics (metabolomics and proteomics) efforts to help construct and decode the largest anthropological, biological, and chemical dataset of plants to inspire new medicines. Previously, he was engaged as an Assistant Professor at the Center for Precision Medicine, Wake Forest Baptist Medical Center, Winston-Salem, USA (2017-2020) focusing in multi-omics towards understanding of human metabolic disorders, i.e., diabetes, obesity, chronic pain, Alzheimer’s disease, autism spectrum disorder, and atherosclerosis across patient and non-human primate cohorts. Here he led the metabolomics efforts in multiple grants (U54, U19, andR01s) as a Co-PI, and consultant. Graduating from IIT Kharagpur, India (2010) in plant biotechnology where he got trained in phytochemistry and mass-spectrometry, he received several Postdoctoral trainings starting with positions at the Center for Chemical Biology, Penang, Malaysia (2010-2013) where he co-led a multinational team that sequenced the rubber tree genome, at the Department of Biology, University of Florida, Gainesville (2013-2015) where he started single cell-type ‘canola plant’ metabolomics. Transitioning to a Staff Scientist I at the Texas Biomedical Research Institute, San Antonio for leading studies in metabo-centric multiomics in non-human primate models, he obtained two pilot grants, i.e., NIH West Coast Metabolomics Center Pilot Grant and Forum Grant. Dr. Misra has published more than 95 peer-reviewed manuscripts, has served as ad hoc reviewer for more than 120 scientific journals, and is an active member of the Society (EMN), MANA, and ASMS.
Statement of Purpose: Two compelling reasons motivated me to apply for an elected Board of Director position:
1) To lead in strategic efforts in helping integration of metabolomics with other omics (proteomics, genomics, microbiome) in a multiomics framework leading to discovery of new scientific insights, in both basic and translational set ups via inception of a “Multiomics Strategic Task Group”. These efforts would include working closely with the omics societies and organizations to help address current challenges and seek actionable solutions.
2) To popularize, promote, help nurture and grow the metabolomics community driven efforts in South-East Asia, India, and China, thereby contributing to the diversity, accessibility, and outreach of the Society. As mass-spectrometry and NMR based metabolomics research advances are experiencing an impressive surge globally across academia and industry, we want a stronger community presence from here. By enabling early to mid-career researchers who drive scientific directions and policies, I want to help bring their voices to be heard for societal transformation. I envision my efforts in coordination with Diversity, Equity & Inclusion and Industry Engagement Task Groups would help accomplish this goal.
Lastly, having served as a member of 2nd batch of EMN Committee, briefly as Metabolomics Association of North America (MANA)’s ECR and BoD, recently as a Womxn in Metabolomics (WomiX) mentor, supporting FAIR practices, I would continue to push for improvement on DEI policies of the Society. It would be a humbling and exciting opportunity for me to serve as one of the Directors of the Society to lead and serve the community globally.
Biography: Sofia Moco is a chemical engineer (2001, Instituto Superior Técnico, Lisbon, Portugal) and a biochemist (PhD, 2007). Since her phD studies, she has been developing metabolomics approaches to study metabolism, through monitoring the dynamics of small molecules / nutrients / drugs / metabolites in various biological systems. She started by studying secondary metabolism in plants, using mass spectrometry (MS) and nuclear magnetic resonance (NMR), to link metabolism to plant physiology and development, during her phD studies at the Biochemistry Laboratory and the Plant Research International, Wageningen University and Research Center, the Netherlands. In 2009, she performed a post-doc at the Institute of Molecular Systems Biology at the ETH Zurich, Switzerland, where she investigated nutrient and bioactive-induced stimuli on central carbon metabolism in microorganisms and higher cells, in the context of cancer. She started as a scientist at Nestle Research, Lausanne, Switzerland, in 2011 where she became a Team leader and a Senior Scientist in Metabolomics in 2016. She developed research by exploring and identifying food bioactives relevant for improving metabolic conditions, such as diabetes, obesity, and ageing, with a particular focus on mitochondrial function and bioenergetics. She started to work on NAD+ biochemistry in 2016, by developing metabolomics approaches, in the context of metabolic diseases, such as ageing and diabetes. She holds expertise in the use of stable isotopes to monitor label incorporation into metabolic intermediates and pathway turnover in vitro (human cell models) and in vivo (mouse models).
Since May 2021 she took a tenure-track position at the VU Amsterdam, the Netherlands, as an Assistant Professor, in the division of Molecular Toxicology, part of the Department of Chemistry and Pharmaceutical Sciences. At the VU, she continues to study metabolism using NMR and LC-MS metabolomics tools.
Statement of Purpose: I have started to work on metabolomics since my phD studies. At the time, I participated on 2nd Plant Metabolomics conference in Potsdam, Germany. I have been implementing metabolomics labs and activities in various areas. I am highly interested on how small molecules can modulate metabolism. For that intend to:
• promote metabolomics as a discipline, by being part of training and education, as well national (VU Amsterdam and Netherlands Metabolomics Centre) and international activities (I am an Associate Editor in Metabolomics for Frontiers Molecular BioSciences)
• foster collaboration between industry and academia (as I have been working on metabolomics in both)
• contribute to the LC-MS and NMR-based metabolomics communities (the latter might need some extra support)
• promote the use of stable isotopes in in vitro and in vivo studies to study metabolic turnover and flux, essential in metabolomics studies
Biographpy: I am Independent Researcher of the National Scientific and Technical Research Council of Argentina (CONICET) and work at the Centro de Investigaciones en Bionanociencias (CIBION). In 2006, I obtained my Ph.D. in analytical and physical chemistry from the University of Buenos Aires. Between 2007 and 2014, I held postdoctoral positions in Italy, France, and the USA. In 2014, I was recruited by CONICET to set up a new laboratory in a new research center in Argentina. I lead the Bioanalytical Mass Spectrometry Group and the Mass Spectrometry facility of CIBION (https://cibion.conicet.gov.ar/mass-spectrometry/?lan=en). My research group develops MS-based metabolomics and lipidomics analytical methods with applications in health and the environment. As well, we have contributed with pipelines for preprocessing LC-MS data for quality control procedures in untargeted workflows. I am co-author of >45 peer-reviewed publications (https://orcid.org/0000-0001-6517-5301). Since 2014, I have coordinated metabolomics courses for South American students, and have participated in strengthening the Latin American community through teaching in Brazil, Colombia, Mexico, and Argentina. Since 2021, I am a founding member of LAMPS (www.lamps-network.org), and I have contributed to engage LAMPS as an international affiliate of the Metabolomics Society. Since 2019, I have been a member of the Metabolomics Society, where I serve on the Membership Committee; and I am a member of the metabolomics quality assurance and quality control consortium. I also served as guest editor for the journal Metabolites, and I am an editorial board member of GigaByte. In 2022, I was awarded the Metabolomics Society Medal.
Statement of Purpose: My intended goals, if elected, include promoting the metabolomics field in the South American region, where I envision growth in the field, larger access to technological developments, and future contributions from this geographical area. In this regard, I would pursue increasing training activities in South America with metabolomics experts from around the globe through in-person and virtual initiatives and, contribute to move this field forward in developing countries. As well, I would promote international collaborative initiatives to generate win-win opportunities. I would like to continue serving on the Metabolomics Society Membership Committee, which has recently contributed to change the fee structure by decreasing fees for individuals who reside in middle- and low-income countries based on the World Bank Atlas Method 2022, to broaden equity and engagement across the membership. If elected, I would also contribute to identify new networking opportunities across the membership and promote new strategies to increase the number of opportunities from developing countries. In particular, I would contribute to find new ways to increase the number of South American representatives in the early career network.
Biography: I am a Junior Group Leader at the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences in Prague. My laboratory develops new computational and experimental approaches for connecting plant natural products to their biosynthetic enzymes, and for engineering novel biosynthetic circuits using synthetic biology tools. Presently I am supervising 4 Ph.D. students and 4 postdocs with both computational and experimental expertise. I myself have an interdisciplinary background in computer science (MSc) and molecular biotechnology (Ph.D.). I first started working in metabolomics in 2006 during my PhD in Japan, where I developed the complete workflows for LC-MS analyses of fission yeast (Schizosaccharomyces pombe). At the same time, I started developing the MZmine software for mass spectrometry data processing, which has become one of my signature projects. During my postdoc at the Whitehead Institute (MIT) in the U.S., I studied the biosynthesis of psychoactive molecules in the kava plant (Piper methysticum). I am fascinated by the complex chemistry and molecular interactions that we can observe in nature, and in my own lab I am trying to apply diverse approaches to address this complexity.
Statement of Purpose: I am a big proponent of data sharing, open science, and open software tools. My research interests are focused on the study of non-model organisms in nature, especially plants. Therefore, if elected to the board of directors, I would like to advocate for these important aspects in metabolomics. I would also advocate for community-driven projects and collaborations, particularly in the area of data processing and tool development. I would be mainly involved in the Data Analysis task group and the Computational Mass Spectrometry task group, and I would like to propose to start a new task group focused on metabolomics in non-model organisms, as opposed to the existing Model Organism Metabolomes task group.
Biography: Dr Estelle Pujos-Guillot, is a senior research scientist with more than 15 years’ experience in mass spectrometry and metabolism. After a PhD in analytical chemistry in 2004 (Lyon I University, France), she joined the Human Nutrition Unit (Clermont-Ferrand) of the French National Research Institute for Agriculture, Food and Environment. She is the scientific director of the Platform for Metabolism Exploration, a mass spectrometry platform dedicated to metabolism studies, and one founding member of MetaboHUB, the national infrastructure in metabolomics and fluxomics.
Her research interests concern nutritional metabolomics and data mining. With her group, she contributes to (1) the development of mass spectrometry-based analytical methods and statistical tools for a better characterization of the first metabolic deviations associated with development of chronic metabolic diseases, (2) the development of models and tools to increase knowledge extraction from high-throughput data. She has been involved, as principal investigator or partner, in several national and international projects focussed on the integration of metabolomics in systems nutrition/medicine and the study of several diseases including metabolic syndrome, diabetes, cancer, and frailty. She is actually leading the WP dedicated to scaling-up metabolomics for large cohorts within the national infrastructure MetaboHUB. She has been member in several scientific societies’ boards of directors, as the French Mass Spectrometry Society (2010-13), the French-speaking Metabolomics and Fluxomics Network (2008-16), and more recently member of the management committee of the Open Multiscale Systems Medicine COST project (2017-20). Today, she has 116 peer reviewed international articles (4522 citations, H-index=32).
Statement of Purpose: Metabolomics has been central in my research. My interest in studying metabolism evolved from setting up dedicated analytical methods and data treatment workflows to the integration of metabolomics in systems nutrition/medicine. Over the past 17 years at INRAE (France), my group has developed metabolomics-based approaches to investigate the first metabolic deviations associated with development of chronic diseases, and study the nutrition-health interactions.
Today, I will be very happy to serve on the Metabolomics Society Board of Directors. As leading a multi-disciplinary group and convinced about the interest and the need of cross-disciplinarity, my first goal will be to continue to promote metabolomics research among different scientific communities (mass spectrometry, statistics, epidemiology, nutrition and systems medicine). I am excited to contribute to the Metabolomics Society efforts to foster interactions that span disciplines and generations, to promote careers of young scientists and accelerate the metabolomics development in emerging countries.
Because data sharing is key to advance all science, I would also like to be very active in the improvement of data reproducibility, both at the level of data production and data science. In particular, I would like to contribute to the activities of the Metabolomic Epidemiology Task group, as well as of the Data Analysis Task Group.
Finally, I think that I can bring my experience of being member of boards of different national scientific societies to be proactive for the organization of events, the ‘daily’ life of the Metabolomics Society, or its evolution in the future.
Biography: Ali Rahnavard is an Assistant Professor in the Department of Biostatistics and Bioinformatics and Computational Biology Institute at George Washington University. His research lab develops novel machine learning, statistical, and visualization techniques and uses omics data to address global health and biomedical challenges. Ali is interested in functional integration of omics data with metabolomics as a core for understanding biology. His work is recognized by awards from numerous national and international organizations, including the National Science Foundation, the Bill and Melinda Gates Foundation, the US Food and Drug Administration, and the National Center for Advancing Translational Sciences. Dr. Rahnavard worked as a computational lead for the Metabolomics Platform and postdoc with the Infectious Disease and Microbiome Program at the Broad Institute of MIT and Harvard and Harvard T.H. Chan School of Public Health. He has developed machine learning techniques to accurately identify and measure metabolites for Liquid Chromatography Mass Spectrometry methods. His lab investigates metabolite dynamics in multiple projects such as pediatric cancer, COVID-19, and pregnancy. Dr. Rahnavard has initiated a program named path2max to promote diversity in biomedical data sciences, which aims to actively recruit students from underrepresented groups and various career levels. More information is available at the Rahnavard Lab website: https://www.rahnavard.org/.
Statement of Purpose: I am honored to be nominated as a candidate for the Board of Directors of the Metabolomics Society. I’m now at a stage in my personal and professional life where I can devote time to serving the society. For the past 10 years, I have worked on metabolomics studies in a variety of capacities, including being a student, serving as a postdoc researcher on the human microbiome project, and being a senior scientist for the metabolomics platform and a member of the Metabolomics Society. Now, as a Principal Investigator, I have established a diverse team of scientists to leverage metabolomics data in translational settings.
Metabolite profiling techniques are evolving rapidly. I will work with platforms in standardizing protocols, data outcomes, connecting platforms, and bridging between profiling techniques and computational techniques to accurately measure and scale data for diverse applications. I was fortunate to be involved in each of these stages of metabolomics studies through my research efforts and will continue to play a role in helping with improvements in standardizing data.
I believe society grows when it incorporates many viewpoints. Because of this, I think diversity is important, and I enjoy working with a diverse team regarding the level of education, scientific background, culture, and ethnicity. Each group has taught me different aspects of work, and I have had a long and enjoyable experience working with diverse scientists. I will help promote diversity in the Metabolomics Society events and activities by fundraising for travel fellowships, specifically considering the inclusion of women, racial and ethnic minorities and advertising the society in underrepresented regions across the globe. It is critical that we as a society maintain a safe and inviting environment for all to fully participate in our diverse activities.
Biography: Nik Rattray is an Associate Professor of Clinical Metabolism at the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) within the University of Strathclyde. In 2012 he completed his Ph.D. in molecular biophysics from School of Pharmacy at the University of Manchester School and has subsequently held postdoctoral roles in the lab of Prof Roy Goodacre in the Manchester Institute of Biotechnology researching ageing/frailty and Dr Caroline Johnson’s metabolomics group within the Yale School of Public Health researching colon cancer.
Since joining SIPBS in 2018, Nik has grown a research group that uses mass spectrometry-based metabolomics, proteomics, and imaging mass spectrometry in ageing research with a focus on developing in-vivo models of frailty and translating this understanding up to the clinic – with two NHS based clinical trials currently underway. He is co-director of the newly formed Strathclyde Centre for Molecular Bioscience (www.scmb.strath.ac.uk) and is PI of two Centers for Doctoral Training that support and develop PhD students in the areas of omics data fusion and biomarker development.
He is a past founding committee member and of the Early Career Member’s Network (EMN) of the Metabolomics Society from 2013-2015 where he acted as chair in 2015. During this time, he also sat on the Board of Directors and Conference and Training committees. Currently he is an active PI member of the Scottish Metabolomics Network (SMN) and sits on the research grants committee of the Dunhill Medical Trust.
Statement of Purpose: Diversity and inclusion sit at the heart of successful science and are fundamental to the continued growth and progressive outlook of our society. Geographical diversity has rightly been a recent focus, with great strides being made through the recognition of our international affiliates. These provide a platform for researchers from all corners of the globe to actively drive the society and benefit from the rich interdisciplinary and collaborative environment.
If I am voted on to the BoD, I would further broaden our approach to inclusion with a focus on role diversity –with an aim to engage and encourage underrepresented technical job roles to become more involved in the Metabolomics Society.
Our conference in Valencia this year was a swelteringly fantastic event with over 850 people attending, but only 9 were registered as technicians. This statistic is not a fair reflection on the percentage contribution our technicians play in our research and success – they are at the heart of our science. As a society we should advocate for all our staff and aim to inspire, develop, and support all needs. The following ideas will begin to address this imbalance:
• Network the technical landscape in Metabolomics (potentially via our Affiliates) to assess the global demographics of technical support and help identify areas (geographical and technical) of need.
• Develop an action plan around visibility, recognition, and career development for technicians within the Metabolomics Society.
• Further develop the DEI Task group to identify/overcome structured inequalities within job roles and maximize participation in our society.
Biography: Dr. Candice Ulmer, a native of South Carolina, graduated from the College of Charleston in 2012 with a B. S. in Chemistry and Biochemistry. While at the College of Charleston, Candice investigated the pharmaceutical photodegradation of NSAIDs using ESI-LC-MS/MS under the direction of Dr. Wendy Cory. Dr. Ulmer graduated (May 2016) with a PhD in Chemistry as a McKnight Doctoral Fellow from the University of Florida in Dr. Richard Yost’s research group. For her doctoral work, she applied UHPLC-HRMS techniques to profile the metabolome/lipidome of human cells and tissues to better understand the disease etiology of Type 1 Diabetes and melanoma skin cancer. Dr. Ulmer’s research comprised experience with various modes of ionization (e.g., MALDI, ESI, APCI, DESI, FlowProbe, and DART). She also incorporated novel stable isotope labeling methodologies such as Isotopic Ratio Outlier Analysis (IROA) to aid in the identification of metabolites as compound identification is still considered a bottleneck in metabolomics studies. In addition to her duties as a graduate student, she was an active researcher with the NIH-funded Southeast Center for Integrated Metabolomics (SECIM). Dr. Ulmer was a member of the Florida mass spec discussion group and the ASMS diversity committee in an effort to increase diversity at conferences and ASMS supported events. Dr. Candice Ulmer was a NIST NRC Post-Doctoral Research Associate (June 2016 – August 2017) and was involved with multi-omic UHPLC-HRMS method development, the first lipidomics interlaboratory study, and experiments that monitored the effects of environmental exposures on human/marine life. Dr. Ulmer is currently a Clinical Chemist Battelle contractor at the Centers for Disease Control and Prevention in Atlanta, GA (National Center for Environmental Health, Division of Laboratory Sciences, Clinical Chemistry Branch). Her responsibilities include the accurate measurement of chronic disease biomarkers and the assessment of clinical analytical methods in patient care.
Statement of Purpose: As an active member of the Metabolomics Society over the past seven years, former elected member of the EMN Committee (2016 – 2018), and current member of the MetSoc Education & Training Committee, I have been actively involved with organizing various aspects of the annual MetSoc meeting, including the pre-meeting workshops. Building on these experiences within MetSoc and leadership roles outside out of the society, I will strive to ensure that our society’s initiatives, programs, and training opportunities continue to reflect the needs and make-up of our diverse membership. If elected, I will work to establish a stronger connection with international affiliates and other professional metabolomics organizations to help advance the field. In addition, I will work to promote and increase the visibility of the society as well as the society’s affiliated, peer-reviewed, open access journal, Metabolites, amongst other established organizations. Historically, in my capacities as co-chair of the MetSoc Diversity & Inclusion committee and member of the MetSoc Membership Committee, I aided in the creation of a demographic data membership questionnaire that will be used to assess recruitment initiatives, the diversity of the membership composition, and member retention. I aim to expand similar initiatives within the society to foster a culture of inclusion and mutual support amongst members by ensuring diversity amongst award recipients, annual conference oral presenters, and the various society committees.
Biography: Lynn Vanhaecke is a Professor at the Laboratory of Integrative Metabolomics (LIMET) at Ghent University, Belgium since 2011 with a 20% appointment at the Institute of Global Food Security at Queen’s University Belfast, UK since 2018. She holds a Ph.D. in Bioscience Engineering (2008) on gut microbial food metabolism. Her team has specific expertise in optimizing and validating high-resolution mass spectrometry (HRMS)-based metabolomics and lipidomics methods with a focus on gastrointestinal matrices (saliva, stool, in vitro digests) and uses the latter to explore metabolic pathways of food- and gut microbiome-related diseases ranging from food allergies to obesity and its comorbidities. She is also particularly interested in the application of ambient ionization-based HRMS (specifically REIMS) for biofluid and food metabolomics and invented the MetaSamp® biofluid sampler in this context. Lynn’s lab has pioneered the field of DNA adductomics in the EU by developing a high-end analytical UHPLC-HRMS platform for untargeted DNA adduct measurements. In recent years, her lab has also gained an interest in the computational part of the metabolomics workflow with dedicated bioinformaticians on staff. Lynn is coordinator of the core facility on small molecule analysis (MSsmall) at Ghent University and a board member of the Nutrigenomics Society (NuGO). She was involved in the Horizon 2020 JPI-HDHL Foodball project and two EIT Food projects on food metabolomics and is now a core partner of the first Flemish Exposome project (Flexigut). LIMET’s metabolomics workflows have been sublicensed to Prodigest under the brand name MetaKey® for commercial application.
Statement of Purpose: If elected to the Metabolomics Society Board of Directors, I would like to contribute to the growth and development of the field as such:
1) Establish a Scientific Task Group on ‘High-throughput Metabolomics’ to take advantage of the critical mass of research activity in this field, as it has the potential to move metabolomics from the lab to the clinic and/or production site. The task group will engage with scientists and vendors active in ambient ionization MS, direct-injection MS, ion mobility, etc. to educate the community on current tools, best practices, and resources (including data analysis) and provide an opportunity for inter-laboratory comparisons and cross-validation with conventional methodologies. Based on this effort, a community perspective paper on the topic should be the first milestone.
2) Contribute to the ‘Precisions Medicine and Pharmacometabolomics’ Task Group in light of my experience with the diet-microbiome-health axis, with the main goal of introducing and informing the community about the complementarity of sampling and analyzing gastrointestinal matrices in an integrated manner using a combination of metabolomics, lipidomics, DNA adductomics, microbiomics, etc.
3) Become a member of the ‘Diversity Equity and Inclusions Task Group’ as a former coordinator of the Diversity task force at my faculty at Ghent University and as an advocate of women in science.
4) Continue to inform my network via Twitter (@ljvhaeck) and Linkedin about events and activities of the Metabolomics Society and complete the installation of the Belgium Metabolomics Society together with colleagues from all institutions active in metabolomics in Belgium.